BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2014 2:47:00 PM | Browse: 869 | Download: 647
Publication Name World Journal of Gastroenterology
Manuscript ID 6933
Country/Territory South Korea
Received
2013-10-30 18:36
Peer-Review Started
2013-11-01 11:35
To Make the First Decision
2013-12-16 18:13
Return for Revision
2013-12-18 11:33
Revised
2014-01-14 17:03
Second Decision
2014-04-16 11:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-04-16 12:15
Articles in Press
2014-05-23 10:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-16 12:41
Publish the Manuscript Online
2014-08-07 10:34
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
Manuscript Source Invited Manuscript
All Author List Woo-Jeong Jeong, Pu-Hyeon Cha and Kang-Yell Choi
Funding Agency and Grant Number
Corresponding Author Kang-Yell Choi, Professor, Translational Research Center for Protein Function Control, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, 134 Shinchon-Dong, Seodemun-Gu, Seoul 120-749, South Korea. kychoi@yonsei.ac.kr
Key Words Colorectal cancer; Epidermal growth factor receptor; Resistance; K-ras mutation; Combinational therapy
Core Tip Personalized treatment of patients with metastatic colorectal cancer (mCRC) based on genetic profiling of individual tumors is considered the future direction of cancer therapy. The important discovery that mutation of the K-ras gene is a predictor of resistance to epidermal growth factor receptor (EGFR) monoclonal antibodies is only the first of a series of genetic predictors and an increasing number of molecular alterations have since been hypothesized to play a role in resistance to anti-EGFR drugs in CRC, including activating mutations in B-Raf and PIK3CA, and loss of expression of PTEN. A comprehensive molecular characterization of mCRC and a better understanding of the functional interactions within the RTK-activated intracellular pathway will be necessary in order to select the most appropriate therapy for each individual patient.
Publish Date 2014-08-07 10:34
Citation Jeong WJ, Cha PH, Choi KY. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9862-9871
URL http://www.wjgnet.com/1007-9327/full/v20/i29/9862.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i29.9862
Full Article (PDF) WJG-20-9862.pdf
Full Article (Word) WJG-20-9862.doc
Manuscript File 6933-Review.docx
Answering Reviewers 6933-Answering reviewers.pdf
Copyright License Agreement 6933-Copyright assignment.pdf
Peer-review Report 6933-Peer reviewer(s).pdf
Scientific Editor Work List 6933-Scientific editor work list.doc